The Bull Rankings scorecard — our quality-growth score is 19.1 / 100, built from three pillars scored 0–100: Quality 16, Growth 87, Value 0 (valuation is judged against sector peers).
The thesis
Ultragenyx sits on a growth‑only track. Our model gives it a 19.1/100 score, with a Growth pillar of 87 and a Value pillar of 0. The 87 tells us the company is scaling fast—revenue grew 17.5 % YoY in the trailing twelve months—yet the 0 Value score flags a price that is already steep relative to peers. The single sharpest argument for buying is that the company’s pipeline is expanding at a pace that current multiples cannot fully absorb.
What the business actually is
Ultragenyx’s revenue engine is a portfolio of orphan drugs. Crysvita (burosumab) treats X‑linked hypophosphatemia and tumor‑induced osteomalacia. Mepsevii is an enzyme replacement for Mucopolysaccharidosis VII, while Dojolvi addresses long‑chain fatty acid oxidation disorders. Evkeeza (evinacuma) targets a rare lipid disorder. These products are sold in North America, Latin America, Europe, the Middle East, Africa, and the Asia‑Pacific, with a focus on rare and ultra‑rare genetic diseases. The pipeline’s breadth mitigates the risk of any single indication underperforming.
Why it can (or can't) keep compounding
The moat is built on regulatory exclusivity and high switching costs. Each drug enjoys orphan drug status, granting market exclusivity and pricing power. The company’s Diluting shareholders signal warns that future equity issuances could erode ownership, but the current beta of 0.32 shows limited volatility, implying a stable cash‑flow environment once approvals materialize. Margins are currently ‑81.7 %, a reflection of heavy R&D spend, yet the Revenue growth of 17.5 % indicates that the company is successfully converting R&D into sales. If the pipeline continues to clear regulatory hurdles, the revenue base will expand, and the high‑cost, high‑margin nature of specialty drugs will preserve profitability.
The valuation question
The price already assumes a P/S of 2.1. With no positive free cash flow, the reverse‑DCF offers no implied growth rate. Our model’s Growth pillar of 87 is driven by the 17.5 % revenue growth, but the Value pillar of 0 tells us the market is pricing in a premium. The analyst consensus 1‑year target of $28.05 and a range of $18–$40 suggest that some analysts expect a 80 % upside from today’s level. The lack of a reverse‑DCF read means we must rely on multiples and the growth narrative. If the company can bring Crysvita and Mepsevii to broader indications, the P/S could justify a higher multiple, but until then the 2.1 multiple is already aggressive for a biotech with negative margins.
The bear case
The strongest skeptic points to the negative profit margin of ‑81.7 % and the free cash flow of ‑$489 m. These figures show the company is still burning cash at a high rate. If the pipeline stalls or pricing pressure mounts, the company could be forced to cut R&D spend, slowing growth. The Diluting shareholders signal confirms that capital needs may lead to equity dilution, eroding shareholder value. A confirmation would be a further decline in revenue growth or a new negative cash‑flow quarter.
What would change our mind
- Revenue growth falling below 10 % YoY would weaken the 87 Growth pillar and suggest the pipeline is stalling.
- Profit margin improving to a positive figure would lift the Value pillar, indicating the company is moving toward profitability.
- A new equity issuance that dilutes shareholders would confirm the model’s cautionary signal and could trigger a price correction.
If any of these thresholds are crossed, the current thesis would need to be revisited.